3. Nanobioconjugate carrying both tumor targeting 2C5 mAb and EGFR AON (P AON/2C5) significantly inhibits EGFR expression on EGFR positive breast cancer cells in vitro as compared to naked EGFR AON. This evidence concerns the gene EGFR and neoplasm.